相关实验视频
Updated: Jul 13, 2025

12:23
Granulocyte-dependent Autoantibody-induced Skin Blistering
Published on: October 12, 2012
10.5K
耐火性球状皮被reslizumab成功治疗:一种可能的新疗法
Hyeok-Jin Kwon1, Ki-Ho Kim1, Jung-Ho Yoon2
1Department of Dermatology, College of Medicine, Dong-A University, Busan, Korea.
Annals of dermatology
|October 19, 2023
概括
作为一种干白素-5 (IL-5) 抑制剂的reslizumab成功地治疗了一名对其他疗法耐药的血栓性皮虫 (BP) 患者. 这表明IL-5是治疗这种自身免疫性水泡性疾病的潜在治疗点.
科学领域:
- 免疫皮肤学 免疫皮肤学
- 自免疫性泡性疾病 自免疫性泡性疾病
- 埃索诺菲尔生物学的生物学
背景情况:
- 囊性皮虫 (BP) 是一种严重的自身免疫性水泡性疾病,患病率和死亡率很高.
- 乙氨基在血压病原发生过程中起着至关重要的作用,存在于血清,组织和泡液中.
- 向乙氨基基基调解剂代表了对高血压的潜在精确治疗策略.
研究的目的:
- 为了研究reslizumab的疗效,一种抗干乐素-5 (IL-5) 单克隆抗体,在这种类固醇和奥马利祖马布耐药的型皮虫病的情况下.
- 探索针对IL-5作为BP新治疗策略的潜力.
主要方法:
- 一个患者的病例报告,患者患有不耐火的型皮虫.
- 进行reslizumab的使用,以向interleukin-5.
- 评估治疗反应和临床结果.
主要成果:
- 通过使用reslizumab成功治疗类固醇和奥马利祖马布耐药的型皮虫.
- 在一个具有挑战性的BP病例中证明reslizumab的治疗潜力.
结论:
- 介质素-5 (IL-5) 是一个可行的和特定的生物点在公牛皮虫的免疫病原发生.
- 雷斯利祖马布代表了一种新的治疗方式,用于治疗不耐火的型皮虫.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
134
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
134
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
148
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
148
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
170
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
170
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
122
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
122
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
312
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
312

